EDE. M. Dolya

E. M. Dolya

*This is an algorithmically generated author record based on publicly available information.

E. M. Dolya has a total of 121 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The role of single nucleotide polymorphisms of VEGF gene in the development of cardiovascular diseases

    by A. S. Gaffarova, I. A. Yatskov, V. A. Beloglazov, E. S. Ageyeva, E. M. Dolya

    Cardiovascular diseases (CVD) are the main cause of mortality in general population. Pathophysiology underlying CVD development includes inflammation, endothelial dysfunction, oxidative stress, atherosclerosis, fibrosis, dyslipidemia and thromboembolism. Endothelial dysfunction affects the balance of endothelium-dependent vasoconstriction and vasodilation by increasing cytokine levels, adhesion molecule expression, leukocyte and monocyte migration, and platelet activation. The vascular endothelial growth factor (VEGF) family is an important component of angiogenesis involved in inducing migration and proliferation of endothelial cells by modulating vascular permeability and blood clotting. The VEGF family includes 5 proteins, of which VEGF-A, VEGF-B and PlGF (placental growth factor) regulate angiogenesis, and VEGF-C and VEGF-D (c-Fos-induced growth factor, FIGF) regulate lymphangiogenesis. VEGF-A is a key factor in the angiogenesis and collateral circulation (arteriogenesis) mediated by the binding of VEGF-A to the VEGFR-1 (Flt-1) and VEGFR-2 (KDR) receptors. As a result of our search, an increased risk of coronary heart disease is expected in the case of detection of certain single oligonucleotide polymorphisms (SNPs) in VEGF-A gene, in particular: rs3025039, rs699947, rs2010963, rs1570360 and rs7667298. VEGF-D is a secreted factor that regulates lymphangiogenesis, angiogenesis, and endothelial proliferation through interaction with VEGFR2 (KDR). Some studies have demonstrated an increase in VEGF-D levels caused by rs192812042 and rs234500 polymorphisms in patients with acute and chronic coronary syndromes, thus suggesting the role of VEGF-D in the formation of CVD by involving lymphangiogenesis, as well as modulating angiogenesis. Genotyping of patients at CVD risk with identification of multiple VEGF SNPs will enable timely diagnostics of patients with initially increased risk of developing cardiovascular pathology and prescribe treatment and measures, prevent development of acute cardiovascular pathology and reduce mortality caused by CVD.

  • Open Access

    2023 All-Russian screening for hypertension: results

    by О. П. Ротарь, I. N. Ilyanova, M. A. Boyarinova, E. V. Moguchaya, K. M. Tolkunova, V. A. Dyachkov, O. A. Rubanenko, A. O. Rubanenko, O. E. Gaberman, E. Yu. Gubareva, et al.

    Aim. To assess awareness of blood pressure (BP) level, adherence to therapy and achievement of target BP in residents of Russian regions as part of the 2023 hypertension (HTN) screening campaign.Material and methods. During May 2023, 4613 participants from 23 cities of Russia took part in the screening. Participation was voluntary without restrictions on sex. All patients aged over 18 years. During screening, BP and pulse were measured three times using automatic or mechanical BP monitors, and a questionnaire about behavioral risk factors, concomitant diseases and therapy was filled out. HTN was diagnosed with systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg and/or taking antihypertensive therapy (AHT).Results. The analysis included data from 4585 respondents aged 18 to 95 years with an average age of 45 [28;59] years, of which 1729 were men (37,7%). The proportion of hypertensive patients was 49,6%. Among them, 62,8% took AHT and achieved target BP in 76,6% and 45,7% with the target BP criterion Conclusion. The data obtained indicate, on the one hand, a continuing insufficient level of awareness about high BP and the use of antihypertensive drugs among the population, but there is a tendency to improve the effectiveness of the treatment of hypertension, including the use of fixed-dose combinations of antihypertensive drugs.


  • Open Access

    Hypertension control during the COVID-19 pandemic: results of the MMM2021 in Russia

    by О. П. Ротарь, A. M. Erina, M. A. Boiarinova, E. V. Moguchaia, E. P. Kolesova, K. M. Tolkunova, A. R. Gorshevaya, K. A. Kovalenko, E. A. Smirnova, Ya. A. Belenikina, et al.

    Repetitive quarantines and social restrictions during the coronavirus disease 2019 (COVID-19) pandemic have negatively affected the population health in general, and the control of hypertension (HTN) in particular.Aim. To evaluate the control of HTN in the Russian population during the COVID-19 period based on the results of screening for HTN May Measurement Month 2021 (MMM2021).Material and methods. During May-August 2021, 2491 participants from 11 Russian regions took part in the screening. Participation was voluntary without restrictions on sex. All participants were over 18 years of age. During the screening, blood pressure (BP) was measured three times using automatic and mechanical BP monitors. In addition, a questionnaire was filled out on behavioral risk factors, comorbidities and therapy. HTN was diagnosed with systolic BP ≥140 mmHg and/ or diastolic blood pressure ≥90 mmHg and/or taking antihypertensive therapy. The questionnaire included questions about prior COVID-19, vaccinations and their impact on the intake of antihypertensive drugs.Results. The analysis included data from 2461 respondents aged 18 to 92, of which 963 were men (39,1%). The proportion of hypertensive patients was 41,0%, while among them 59,0% took antihypertensives and 30,9% were effectively treated. In comparison with pre-pandemic period according to MMM2018-2019, the higher proportion of HTN patients in the Russian sample was revealed during MMM2021 (41,0% vs 31,3%, pConclusion. According to HTN screening in Russia, there is persistent ineffective control of HTN, which may be due to both the worsening pattern of behavioral risk factors, limited access to healthcare during COVID-19, and the inertia of physicians and low adherence of patients due to the asymptomatic HTN course in the majority.


  • Open Access

    Hypertension control during the COVID-19 pandemic: results of the MMM2021 in Russia

    by О. П. Ротарь, A. M. Erina, M. A. Boiarinova, E. V. Moguchaia, E. P. Kolesova, K. M. Tolkunova, A. R. Gorshevaya, K. A. Kovalenko, E. A. Smirnova, Ya. A. Belenikina, et al.

    Repetitive quarantines and social restrictions during the coronavirus disease 2019 (COVID-19) pandemic have negatively affected the population health in general, and the control of hypertension (HTN) in particular.Aim. To evaluate the control of HTN in the Russian population during the COVID-19 period based on the results of screening for HTN May Measurement Month 2021 (MMM2021).Material and methods. During May-August 2021, 2491 participants from 11 Russian regions took part in the screening. Participation was voluntary without restrictions on sex. All participants were over 18 years of age. During the screening, blood pressure (BP) was measured three times using automatic and mechanical BP monitors. In addition, a questionnaire was filled out on behavioral risk factors, comorbidities and therapy. HTN was diagnosed with systolic BP ≥140 mmHg and/ or diastolic blood pressure ≥90 mmHg and/or taking antihypertensive therapy. The questionnaire included questions about prior COVID-19, vaccinations and their impact on the intake of antihypertensive drugs.Results. The analysis included data from 2461 respondents aged 18 to 92, of which 963 were men (39,1%). The proportion of hypertensive patients was 41,0%, while among them 59,0% took antihypertensives and 30,9% were effectively treated. In comparison with pre-pandemic period according to MMM2018-2019, the higher proportion of HTN patients in the Russian sample was revealed during MMM2021 (41,0% vs 31,3%, pConclusion. According to HTN screening in Russia, there is persistent ineffective control of HTN, which may be due to both the worsening pattern of behavioral risk factors, limited access to healthcare during COVID-19, and the inertia of physicians and low adherence of patients due to the asymptomatic HTN course in the majority.


  • Open Access

    Modern view on the etiopathogenesis of heart rhythm disorders and methods of their correction in pregnant women

    by R. Kh. Useinova, A. N. Sulima, A. N. Rybalka, D. A. Beglitse, Z. S. Rumyantseva, P. N. Baskakov, M. A. Dizha, E. M. Dolya

    Introduction. Issues of etiopathogenesis for various cardiovascular disorders in the structure of extragenital diseases during pregnancy pose an urgent problem and represent a global topic for further scientific research. Due to the high frequency of heart rhythm disorders in pregnant women, it is necessary to improve their management.Aim: to analyze data from the current literature on the etiopathogenesis of arrhythmias during gestation and effective methods of their correction.Materials and Methods. Literature sources of electronic databases PubMed/MEDLINE, Medscape, Google Scholar, Embase, Ovid Healthstar, Cochrane, eLibrary, CyberLeninka and scientific articles in peer-reviewed open access journals published across the last 25 years, including basic research on this pathology have been analyzed. The search in databases used keywords and their combinations in Russian and English: "arrhythmias", "arrhythmias in pregnancy", "pathogenesis of gestational arrhythmias".Results. There have been analyzed major aspects of the etiology and pathogenesis of gestational arrhythmias as well as potential causes for developing first-time rhythm disorders in pregnant women and features of the gestational period as a predictor of emerging arrhythmias in patients with pre-existing pathology of the cardiovascular system are determined. The article describes the most common rhythm disorders and acceptable ways to correct them, taking into account the latest recommendations and research in this area.Conclusion. The authors concluded that the etiopathogenesis of rhythm disorders during pregnancy and their treatment methods require further examination.


  • Open Access

    May Measurement Month 2019: adherence to treatment and hypertension control in Russia

    by О. П. Ротарь, K. M. Tolkunova, V. N. Solntsev, A. M. Erina, M. A. Boyarinova, A. S. Alieva, E. V. Moguchaya, E. P. Kolesova, E. I. Pavlyuk, O. M. Posnenkova, et al.

    The International Society of Hypertension and the World Hypertension League initiated a blood pressure screening study called May Measurement Month 2019 (MMM19) to improve the detection of elevated blood pressure (BP) and to assess BP control in patients with hypertension (HTN).Aim. To assess adherence to treatment of the hypertensive population according to MMM19 campaign in Russia.Material and methods. During May 2019, 5394 people from 21 regions of Russia took part in the screening. Participation was voluntary and did not imply gender restrictions; all subjects were over 18 years of age. During the screening, BP was measured three times using electronic and mechanical sphygmomanometers, as well as a questionnaire on the diabetes, history of cardiovascular events, smoking, and alcohol consumption was filled. Information was also collected on the date of last BP check and the administration of statins, acetylsalicylic acid and antihypertensive drugs. Data on height and body weight was obtained from respondents.Results. The analysis included data from 5274 participants aged 18 to 96 years (men — 1834 (34,8%)). Median age was 25 years, quartiles — 20 and 49 years. According to MMM19 data, the proportion of HTN patients in the Russian population was 31,9%, and with the exception of participants under 25 years old — 51,5%. Patients with HTN over 25 years old take antihypertensive therapy in 73,6%; 38,6% are characterized by irregular drug intake. Only 11,8% of men and 17,2% of women reach the target blood pressure Conclusion. According to MMM19 in Russia, only a third of high-risk patients measured BP over the past 12 months. There is also low adherence to antihypertensive therapy and inadequate control of HTN. Patients with HTN and a history of cardiovascular events are more likely to take antihypertensives regularly.